Profilo
Michl Binderbauer is the founder of TAE Technologies, Inc. He is currently the Director at TAE Life Sciences LLC.
Posizioni attive di Michl Binderbauer
| Società | Posizione | Inizio |
|---|---|---|
TAE Technologies, Inc.
 TAE Technologies, Inc. Electric UtilitiesUtilities Tae Technologies, Inc. develops plasma fusion technologies. It offers plasma fusion technology that provides electricity generation and nuclear power plants waste elimination. The company was founded in 1998 and is headquartered in Foothill Ranch, CA. | Fondatore | - |
TAE Life Sciences LLC
 TAE Life Sciences LLC Pharmaceuticals: MajorHealth Technology TAE Life Sciences LLC is a privately-held biotechnology company that is developing a new biologically-targeted radiation therapy based on boron neutron capture therapy (BNCT). The company is based in Foothill Ranch, CA. The company is committed to developing next-generation targeted boron drugs and a low-energy accelerator-based neutron source that can treat patients with the most aggressive and recurrent cancers. TAE Life Sciences' Alphabeam™ neutron system and targeted boron drugs are currently in development and have not been approved for sale. Robert W. Hill has been the CEO of the company since 2019. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
TAE Technologies, Inc.
TAE Technologies, Inc. Electric UtilitiesUtilities Tae Technologies, Inc. develops plasma fusion technologies. It offers plasma fusion technology that provides electricity generation and nuclear power plants waste elimination. The company was founded in 1998 and is headquartered in Foothill Ranch, CA. | Utilities |
TAE Life Sciences LLC
TAE Life Sciences LLC Pharmaceuticals: MajorHealth Technology TAE Life Sciences LLC is a privately-held biotechnology company that is developing a new biologically-targeted radiation therapy based on boron neutron capture therapy (BNCT). The company is based in Foothill Ranch, CA. The company is committed to developing next-generation targeted boron drugs and a low-energy accelerator-based neutron source that can treat patients with the most aggressive and recurrent cancers. TAE Life Sciences' Alphabeam™ neutron system and targeted boron drugs are currently in development and have not been approved for sale. Robert W. Hill has been the CEO of the company since 2019. | Health Technology |
- Borsa valori
- Insiders
- Michl Binderbauer
